

CURRENT REPORT

Report date: 07.03.2025

Name of issuing company: Antibiotice SA

Headquarters: Iași, str. Valea Lupului nr. 1, zip code 707410

<http://www.antibiotice.ro>

E-mail: relatiicuinvestitorii@antibiotice.ro

Telephone/fax no.: 0232 209000 / 0372 065633

Unique registration code in the Trade Register Office: RO1973096

No. in the Trade Register: J1991000285223

Subscribed and paid-up capital: 67,133,804.00 RON

The regulated market trading the securities issued: Bucharest Stock Exchange

Number of shares: 671,338,040

Number of votes: 671,338,040

Main characteristics of the securities issued by the company: nominative shares, nominal value: 0.10 RON

Important event to report:

Visit of IBM Research Vice President Jason Silbergleit to Antibiotice Iasi: Opportunities for innovation in the Romanian pharmaceutical industry

On March 6th, the company hosted the visit of IBM Research Vice President, Jason Silbergleit, and the IBM delegation, for a meeting dedicated to the integration of the latest technologies, such as quantum computing and artificial intelligence, in the future Research and Development Center of Antibiotice Iași, Inova a+. On this occasion, Jason Silbergleit met with Ioan Nani, CEO of Antibiotice Iasi, Gianina Macovei, Executive Director of Research and Development, Ștefania Alexandru, Director of Strategic Planning and Portfolio Management, and a team of young specialists in the fields of research and IT.

The visit took place in the context of the launch of a quantum computing research, education and innovation campus in Iași, in partnership with the American company IBM. This is the first of its kind in Romania and aims to transform the city of Iași into a regional research pole in the field of quantum technologies.

The discussions held at the Antibiotice Iasi headquarters focused on the integration of quantum computing, artificial intelligence and other emerging technologies into the structure of Inova a+. This ultra-modern center, which will benefit from European funding for the production of critical medicines from the Ministry of Investments and European Projects, will become a strategic pillar in the development of innovative therapeutic solutions. Inova a+ will use these technologies to create a digitalized system, which will facilitate rapid drug discovery and improve the efficiency of the testing and validation process.

"Strategic partnerships with global leaders like IBM are essential for the future of Antibiotice Iasi. By integrating leading-edge technologies, we aim to accelerate the discovery of innovative drugs and optimize production processes, thus keeping us at the forefront of the pharmaceutical industry. The opportunity to collaborate with IBM will strengthen our capacity to develop advanced therapeutic solutions and contribute to the creation of a sustainable innovation ecosystem, within a viable partnership between industry, academia and the technology sector," said Ioan Nani, CEO of Antibiotice Iasi.

Strategic partnership with IBM for the digital transformation of Antibiotice Iasi

In 2024, Antibiotice Iasi has entered into a partnership with IBM Corporation to adopt the digital solution SAP S/4HANA, the most advanced enterprise resource planning (ERP) software, which integrates all processes of a company. The adoption of this digital solution will improve the operational efficiency of digitalized processes, accelerate the company's reaction speed and support an efficient response to market needs, in line with the principles of sustainable development.

General Director
ec. Ioan NANI

